- ►diabetesjournals.org F Pistrosch, K Herbrig, B Kindel, J Passauer, … - Diabetes, 2005 - Am Diabetes Assoc Microalbuminuria, an early feature of diabetic nephropathy, indicates intrarenal
endothelial damage. In type 2 diabetes, microalbuminuria is strongly related to
insulin resistance. We therefore investigated whether rosiglitazone, an ... Cited by 111 - Related articles - All 6 versions
- ►ahajournals.org J Hetzel, B Balletshofer, K Rittig, D Walcher … - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc Methods and Results— Short-term treatment (21 days) of healthy subjects (n=10)
did not significantly change blood glucose levels or lipid profile. In contrast,
rosiglitazone significantly increased flow-mediated, endothelium-dependent ... Cited by 104 - Related articles - All 10 versions
- ►endojournals.org R Muniyappa, M Montagnani, KK Koh, MJ … - Endocrine reviews, 2007 - Endocrine Soc Insulin has important vascular actions to stimulate production of nitric oxide
from endothelium. This leads to capillary recruitment, vasodilation, increased
blood flow, and subsequent augmentation of glucose disposal in classical ... Cited by 97 - Related articles - BL Direct - All 5 versions
F Pistrosch, K Herbrig, U Oelschlaegel, S … - Atherosclerosis, 2005 - Elsevier We investigated 10 recently diagnosed type 2 diabetic patients and 10 age and
sex matched healthy control subjects. After baseline examination of metabolic
parameters and EPC, patients received 4 mg rosiglitazone bid for 12 weeks. ... Cited by 93 - Related articles - All 12 versions
E Cersosimo, RA DeFronzo - Diabetes/Metabolism Reviews - interscience.wiley.com Cardiovascular disease affects approximately 60% of the adult population over
the age of 65 and represents the number one cause of death in the United States.
Coronary atherosclerosis is responsible for the vast majority of the ... Cited by 83 - Related articles - BL Direct - All 3 versions
- ►annals.org [PDF] JPH van Wijk, EJP de Koning, MC Cabezas… - Annals of internal medicine, 2005 - Am Coll Physicians Comparison of Rosiglitazone and Metformin for Treating ... Jeroen PH van Wijk,
MD; Eelco JP de Koning, MD, PhD; Manuel Castro Cabezas, MD, PhD; Jos op't Roodt,
BSc; Jorge Joven, MD, PhD; Ton J. Rabelink, MD, PhD; and Andy I. Hoepelman, ... Cited by 74 - Related articles - BL Direct - All 4 versions
PA Sarafidis, GL Bakris - Kidney international, 2006 - nature.com The global epidemic of diabetes mellitus has led to a continuous increase in the
prevalence of diabetic nephropathy over the past years. Thus, diabetic
nephropathy is currently the number one cause of end-stage renal disease in ... Cited by 72 - Related articles - BL Direct - All 4 versions
- ►onlinejacc.org M Hanefeld, N Marx, A Pfützner, W Baurecht, G … - Journal of the American College of Cardiology, 2007 - Elsevier In a 12-week, prospective, double-blind trial, 125 subjects were randomized to
simvastatin or pioglitazone plus placebo or a simvastatin/pioglitazone
combination. We tested changes in hs-CRP by analysis of covariance. A ... Cited by 71 - Related articles - BL Direct - All 25 versions
- ►ahajournals.org U Campia, LA Matuskey, JA Panza - Circulation, 2006 - Am Heart Assoc Methods and Results— The study had a randomized, double-blind,
placebo-controlled, crossover design. Eighty patients with either hypertension
or hypercholesterolemia were enrolled. Insulin sensitivity was assessed by ... Cited by 66 - Related articles - All 6 versions
C Gensch, YP Clever, C Werner, M Hanhoun, … - Atherosclerosis, 2007 - Elsevier PPAR-γ agonists (thiazolidinediones, TZDs) may improve endothelial function
independently of insulin sensitizing. Bone marrow-derived endothelial progenitor
cells (EPC) contribute to neoangiogenesis. Mice were treated with ... Cited by 64 - Related articles - All 11 versions
